Consistently, in vivo limiting dilution assay showed, compared with the sh‐ctrl‐ALDH+/CD44+ fraction, the sh‐ctrl‐ALDH−/CD44− fraction and shGSTP1‐ALDH+/CD44+ fractions showed significantly reduced CSC frequency, tumor incidence, and longer tumor‐free survival, respectively. This evidence concerns the gene CD44 and neoplasm.